Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -1.88.

EBIT: As of FY2026 Q2, the actual value is USD -251.98 M.

Research and Development Expenses

Research and development expenses for COMPASS Pathways plc were $29.2 million for the three months ended June 30, 2026, compared to $30.3 million for the same period in 2025. For the six months ended June 30, 2026, these expenses were $55.7 million, down from $61.2 million for the same period in 2025.

General and Administrative Expenses

General and administrative expenses for COMPASS Pathways plc were $23.2 million for the three months ended June 30, 2026, an increase from $12.6 million for the same period in 2025. For the six months ended June 30, 2026, these expenses totaled $39.6 million, up from $31.3 million for the same period in 2025.

Net Loss

COMPASS Pathways plc reported a net loss of - $253.8 million for the three months ended June 30, 2026, compared to a net loss of - $38.4 million for the same period in 2025. The net loss for the six months ended June 30, 2026, was - $162.6 million, an increase from a net loss of - $56.3 million for the same period in 2025.

Fair Value Change of Warrant Liabilities

The fair value change of warrant liabilities resulted in a - $205.6 million loss for the three months ended June 30, 2026, compared to a - $2.5 million loss for the same period in 2025. For the six months ended June 30, 2026, this change was a - $74.7 million loss, significantly different from a $16.9 million gain in the prior year period.

Cash and Cash Equivalents

Cash and cash equivalents for COMPASS Pathways plc were $433.3 million as of June 30, 2026, an increase from $149.6 million as of December 31, 2025.

Debt

Debt for COMPASS Pathways plc stood at $50.7 million as of June 30, 2026, compared to $31.6 million as of December 31, 2025.

Financial Guidance and Outlook

COMPASS Pathways plc anticipates its current cash position will be sufficient to fund operating expenses and capital expenditure requirements into 2028. The company expects to complete the final New Drug Application (NDA) submission for COMP360 in the fourth quarter of 2026. Subject to FDA approval and DEA rescheduling, a commercial launch of COMP360 is projected for the first half of 2027.